Loading…
← CockpitCompetitor Analysis › HNR1.DE Hannover Rueck SEOpen in the cockpit ↗

Hannover Rueck SEHNR1.DECompetitor analysis, valuation and peers

Germany · EUR·Financials›Life/Health Insurance

German reinsurance company, one of the world's largest, covering life/health and property-casualty risks.

Momentum leader 92
Mkt cap
$39.6B
US dollars, full cap
Free float
50%
of shares outstanding
$/day
$45.2M
20-day average traded
P/B
2.66×
price to book
ROE
22.4%
delivered
Implied ROE
8.3%
what the price asks
Next earnings
3 days
9 Nov 2026
Close · EUR€293.00
1D-4.4%
1W+1.0%
1M+11.7%
3M+17.0%
6M+24.1%
YTD+10.1%
1Y+17.9%
ATR %2.0%
52w lowhigh5.2% off high

What Hannover Rueck does

German reinsurance company, one of the world's largest, covering life/health and property-casualty risks.

Takes on slices of other insurers' risk in return for a share of their premiums, mostly under treaties covering whole portfolios, and invests those premiums until claims are paid. Talanx, the German insurance group, owns the majority of the shares. Life and health reinsurance sits alongside property-casualty.

Products and services

  • P&C reinsurance
  • Life & health reinsurance

Customers

  • Primary insurance companies worldwide

Where it sits in the supply chain

  • Financials
  • Insurance
  • Reinsurance

What could go right

  • Reinsurance hard market pricing
  • Life/health reinsurance demand in aging markets

What could go wrong

  • Catastrophe loss volatility
  • Reserve adequacy risk in long-tail lines

Moat: narrow (scale, brand). Third or fourth-largest global reinsurer with deep client relationships and diversified risk book.

Headquarters: Hanover, Germany · Founded: 1966 · Employees: 4,078

Named competitors

Hannover Rueck at a glance

Size Hannover Rueck (HNR1.DE) is a Germany Financials company (Life/Health Insurance) with a market value of $39.6B, the 22nd largest of 205 Germany companies the cockpit tracks. Shares closed at €293.00 on 6 Nov 2026.

Performance Over six months the shares gained 24.1%, against +20.6% for the median peer and +2.6% for the Germany market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue fell 2.1% over the last twelve months (peer median +11.5%); the operating margin is 13.5% (peer median 9.3%).

Valuation It trades at 2.66× book value against a peer median of 1.40× (6th most expensive of 20).

Price implies The share price implies a return on equity of about 8.3%; Hannover Rueck delivers 22.4%, so the price asks less than the business earns today.

Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).

Relative performance

10012011 May 202611 Aug 20266 Nov 2026HNR1.DE 123Peer median 120
Six months, rebased to 100: Hannover Rueck against the median of its 20 peers (local-currency closes).

Hannover Rueck financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€28.6B€28.8B€28.7B€26.3B€25.7B
Revenue growth—0%+9%+3%—
Net income€2.73B€2.64B€2.33B€1.82B€781M
Free cash flown/an/an/a€5.79B€4.95B
Capital expenditure€0€0€0€0€0
Total debt€4.13B€4.14B€4.67B€4.88B€5.51B

Quarterly statements and history in the cockpit →

Hannover Rueck competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%-10%0%+10%61788750PRUTLX2882SLHNBAJAJFINSV032830LICINNMFCMUV2SBILIFE2883RGACRBGEQH8795HDFCLIFESDLFHNR1.DE6-month return →1-month return →
Up and to the right = strong over both horizons. Hannover Rueck is the large dot.

Fundamentals: return on equity against price-to-book

-150%-100%-50%0%00×200×400×61788750TLXSLHNSBILIFEHDFCLIFESDLFHNR1.DEReturn on equity →Price / book →
A bank or insurer earning more on its equity usually trades at a higher multiple of book; points far above the trend are priced for more. Hannover Rueck is the large dot.

Capital: ROE delivered against the ROE the price implies

0%25%50%75%100%0%50%100%61788750PRUSLHNBAJAJFINSV032830SBILIFECRBGHDFCLIFEHNR1.DEROE delivered →ROE the price implies →
Above the diagonal = the price asks for a higher return on equity than the business earns today. Hannover Rueck is the large dot.

Hannover Rueck competitors and peer comparison

Head to head with its named competitors (HNR1.DE vs MUV2.DE vs SREN.SW vs SCR.PA)
CompanyMarket cap6M returnRevenue growthROEPrice / bookImplied ROE
Hannover Rueck HNR1.DE$39.6B+24%-2%22%2.66×8.3%
Munchener Ruckversicherungs-Gesellschaft MUV2.DE$80.3B+22%0%21%2.13×9.0%
Swiss Re SREN.SW$50.6B+27%-12%20%2.27×6.1%
Scor SCR.PA$6.96B+10%-4%19%1.44×9.8%
Reinsurance Group of America RGA$17.1B+24%+20%12%1.25×8.0%

How Hannover Rueck compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hannover Rueck against its 20 peers (data as of 6 Nov 2026)
MeasureHNR1.DEPeer medianRank in peer set
1-month return+11.7%+2.4%highest of 21
6-month return+24.1%+20.6%7th highest of 21
Return on equity22.4%12.8%highest of 21
Price / book2.66×1.40×6th most expensive of 20
Trailing P/E12.9×11.7×9th most expensive of 20
ROE the price implies8.3%9.6%9th least demanding of 19
ROE delivered22.4%13.1%highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthROEPrice / bookImplied ROEDelivered ROE
Hannover Rueck HNR1.DEGermany$39.6B+24%-2%22%2.66×8.3%22.4%
Japan Post Hldgs 6178.TJapan$39.0B+24%0%5%0.62×4.4%4.5%
Daiichi Life 8750.TJapan$39.0B+18%+17%14%1.34×8.1%13.6%
Prudential Financial PRUUnited States$41.1B+20%+4%13%1.39×11.4%12.6%
Talanx TLX.DEGermany$37.6B+24%+2%20%2.33×10.2%19.8%
Cathay Financial Hldg 2882.TWTaiwan$47.0B+42%-16%15%1.40×7.0%14.6%
Swiss Life SLHN.SWSwitzerland$33.0B+14%0%20%4.25×15.4%20.0%
Bajaj Finserv BAJAJFINSV.NSIndia$31.6B+2%+17%13%3.55×54.3%13.3%
Samsung Life 032830.KSSouth Korea$31.0B-6%+13%3%0.29×4.5%3.2%
Life Insurance Corp. of India LICI.NSIndia$53.0B-3%+11%7%0.68×11.8%n/a
NN Group N.V. NN.ASNetherlands$22.4B+4%+39%9%1.08×6.9%9.2%
Manulife Financial MFC.TOCanada$72.2B+13%+18%13%2.22×13.0%12.9%
Munchener Ruckversicherungs-Gesellschaft MUV2.DEGermany$80.3B+22%0%21%2.13×9.0%21.4%
SBI Life Insurance SBILIFE.NSIndia$18.9B-5%+18%14%8.72×105.4%13.7%
Kgi Financial 2883.TWTaiwan$17.3B+60%+32%14%1.33×7.1%14.4%
Reinsurance Group of America RGAUnited States$17.1B+24%+20%12%1.25×8.0%11.7%
Corebridge Financial CRBGUnited States$14.9B+25%+10%22%2.41×19.3%21.7%
Equitable EQHUnited States$14.1B+24%+6%-183%n/an/an/a
T&d 8795.TJapan$14.0B+21%+6%9%1.32×5.6%9.3%
HDFC Life Insurance HDFCLIFE.NSIndia$13.0B-10%+19%11%6.31×72.0%11.2%
Standard Life SDLF.LUnited Kingdom$12.5B+25%+135%-179%38.09×n/a-179.3%

Questions

Who are Hannover Rueck's main competitors?
Named competitors: Munich Re (MUV2.DE), Swiss Re (SREN.SW), SCOR (SCR.PA), RGA (RGA). The cockpit's measured peer set (industry) also includes Japan Post Hldgs (6178.T), Daiichi Life (8750.T), Prudential Financial (PRU), Talanx (TLX.DE), Cathay Financial Hldg (2882.TW), Swiss Life (SLHN.SW).
Is Hannover Rueck expensive compared with its peers?
On price / book it trades at 2.66× against a peer median of 1.40×, 6th most expensive of 20 in its peer set. The share price implies a return on equity of about 8.3%; Hannover Rueck delivers 22.4%, so the price asks less than the business earns today.
How has Hannover Rueck stock performed?
Over six months to 6 Nov 2026 the shares returned +24.1% against +20.6% for the median peer; over one year +17.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.